Current Report Filing (8-k)
22 June 2019 - 6:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2019
CYTOMX THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-37587
|
|
27-3521219
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650)
515-3185
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.00001
|
|
CTMX
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
CytomX Therapeutics, Inc. (the Company) held its 2019 Annual Meeting of Stockholders (the Annual Meeting) on
June 19, 2019. On the April 22, 2019 record date, there were 45,311,464 shares of the Companys common stock outstanding with each such share being entitled to one vote per share.
At the Annual Meeting, 38,541,136 shares of the Companys common stock were voted in person or by proxy for the four proposals set forth
below, each of which is described in the Companys Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2019.
Proposal 1.
The Companys stockholders elected the Class I director nominees below to the Companys Board of Directors to hold office
until the 2022 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOMINEE
|
|
FOR
|
|
|
AGAINST
|
|
|
ABSTAIN
|
|
|
BROKER
NON-VOTES
|
|
Sean A. McCarthy, D. Phil.
|
|
|
24,359,109
|
|
|
|
5,769,149
|
|
|
|
1,431,873
|
|
|
|
6,981,005
|
|
John Scarlett, M.D.
|
|
|
17,316,885
|
|
|
|
12,809,132
|
|
|
|
1,434,114
|
|
|
|
6,981,005
|
|
Proposal 2.
The Companys stockholders ratified the selection of Ernst & Young LLP as the independent
registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
|
|
|
|
|
|
|
FOR
|
|
AGAINST
|
|
ABSTAIN
|
|
BROKER
NON-VOTES
|
36,897,291
|
|
211,579
|
|
1,432,266
|
|
0
|
As a routine proposal under applicable rules, no broker
non-votes
were
recorded in connection with this proposal.
Proposal 3.
The approval, on a
non-binding,
advisory basis, of
the compensation of the Companys named executive officers:
|
|
|
|
|
|
|
FOR
|
|
AGAINST
|
|
ABSTAIN
|
|
BROKER
NON-VOTES
|
29,163,431
|
|
944,368
|
|
1,452,332
|
|
6,981,005
|
Proposal 4.
The
non-binding,
advisory vote regarding the frequency of future
advisory votes by stockholders on the compensation of the Companys named executive officers:
|
|
|
|
|
|
|
|
|
1 YEAR
|
|
2 YEARS
|
|
3 YEARS
|
|
ABSTAIN
|
|
BROKER
NON-VOTES
|
29,136,655
|
|
101,024
|
|
875,938
|
|
1,446,514
|
|
6,981,005
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
Date: June 21, 2019
|
|
CYTOMX THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
|
/s/ Lloyd Rowland
|
|
|
|
|
Lloyd Rowland
|
|
|
|
|
Senior Vice President and General Counsel
|
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2024 to May 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From May 2023 to May 2024